Evidence map›Paper›PMID 40683940›Full record

ArticleScientific reports2025

TFEB overexpression alleviates autophagy-lysosomal deficits caused by progranulin insufficiency.

Wren O Nader, Kaylan S Brown, Nicholas R Boyle, Azariah K Kaplelach, Shaimaa M Abdelaziz, Skylar E Davis, Qays Aljabi, Ahmad R Hakim, Amelia G Davidson, Giacynta A Vollmer and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wren O NaderKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Kaylan S BrownKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Nicholas R BoyleKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Azariah K KaplelachKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Shaimaa M AbdelazizKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Skylar E DavisKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Qays AljabiKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Ahmad R HakimKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Amelia G DavidsonKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Giacynta A VollmerKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Leah C WrightKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
J Bailey EcholsKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Joelle SaadKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Nicholas S PenaKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Andrew E ArrantKillion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA. andrewarrant@uabmc.edu.

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
UAB Alzheimer's Disease Research CenterP30AG086401 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Rati Chkheidze · 2024 to 2026
$17.1M
CTSA Predoctoral T32 at the University of Alabama at BirminghamT32TR004767 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Jennifer S Pollock · 2024 to 2026
$1.7M
Abnormal Late Endosomal Trafficking in Frontotemporal Dementia due to Progranulin MutationR00AG056597 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ARRANT, ANDREW EMMETT · 2019 to 2021
$747k
The cause and effect of reduced ò-glucocerebrosidase activity in the setting of progranulin deficiencyF30AG071114 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BOYLE, NICHOLAS RYAN · 2021 to 2024
$179k
NCATS NIH HHS T32 TR004767NCI NIH HHS P30 CA013148NIAID NIH HHS P30 AI027767NIA NIH HHS F30 AG071114NIA NIH HHS F30AG071114NIA NIH HHS P30 AG086401NIA NIH HHS R00 AG056597NIA NIH HHS R00AG056597
6 · The paper itself

Abstract

Progranulin is a pro-protein that is necessary for maintaining lysosomal function. Loss-of-function progranulin (GRN) mutations are a dominant cause of frontotemporal dementia (FTD). Brains of people with FTD due to GRN mutations accumulate lysosomal storage material and exhibit increased expression of lysosomal transcripts, which may be driven by TFEB and related transcription factors. While this may be a compensatory response to lysosomal impairment, overproduction of lysosomal proteins may also contribute to FTD pathogenesis. To investigate how TFEB may contribute to disease in people with GRN mutations, we analyzed the effects of TFEB overexpression in progranulin-insufficient cells and mice. We generated GRN knockout HEK-293 cells (GRN KO cells), which exhibited increased nuclear localization of TFEB and expression of lysosomal transcripts, but impaired autophagy. TFEB overexpression in GRN KO cells further increased lysosomal transcripts and partially normalized autophagy. We next injected an AAV vector expressing mouse Tfeb (AAV-TFEB) into the thalamus of Grn

Indexed as

AutophagyBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsFrontotemporal DementiaLysosomesProgranulinsAnimalsHEK293 CellsHumansMiceMice, KnockoutBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsGrn protein, mouseProgranulinsTcfeb protein, mouseTFEB protein, humanAutophagyLysosomesProgranulinTFEB

Identifiers

PMID40683940
PMCPMC12276339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.